MD Anderson-led Phase II trial suggests neoadjuvant immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas After treatment with a combination of immunotherapy and ...
A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses against aggressive soft tissue sarcomas, based on early phase II data ...
New research from Dartmouth Health and Dartmouth Cancer Center reveals a glowing molecule designed to highlight soft-tissue sarcomas during surgery, paving the way for more precise tumor removal and ...
The aim of this pilot study was to evaluate the feasibility and utility of real-time tumor fluorescence-guided surgery (TFGS) with near-infrared fluorescence indocyanine green (NIRF-ICG) for the ...
A new end-to-end PET imaging approach for osteosarcoma can rapidly and reliably distinguish tumor tissue from normal tissue and accurately assess surgical margins in real time. The novel platform, ...
Researchers and biomedical engineers from Dartmouth Health, Dartmouth Cancer Center and the Thayer School of Engineering at Dartmouth College have discovered a new fluorescent molecule that makes ...
Please provide your email address to receive an email when new articles are posted on . Management and treatment of sarcoma takes a multidisciplinary team. The Musculoskeletal Tumor Registry aims to ...
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results